What Does Gilead Sciences (GILD) Do? — A Complete Overview of Its Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters
Gilead Sciences (GILD) is a major U.S. biopharmaceutical company and a global leader in HIV and hepatitis treatments. HIV revenue centered on Biktarvy, the expansion of its oncology pipeline, and the rollout of new PrEP products such as Yeztugo are its key growth pillars, while clinical trial results, patent-expiration cycles, and acquisition-related intangible-asset amortization are the main variables affecting its earnings, stock price, and outlook.
🏢 What kind of company is Gilead Sciences?
Gilead Sciences (GILD) is a global biopharmaceutical company founded in the United States in 1987. Since its founding, the company has distinguished itself in antiviral drug development and has established a leading global position in HIV and hepatitis treatments.
It operates a diversified pharmaceutical portfolio spanning HIV treatments such as Biktarvy, hepatitis C and B treatments, oncology products including Trodelvy and antibody-drug conjugates as well as cell therapies, and inflammation and other antiviral medicines. It holds a leading position in the global HIV treatment market.
💰 How does Gilead Sciences make money?
| Business segment | Revenue contribution | Description |
|---|---|---|
| HIV treatments | Core business | Biktarvy, Descovy, Yeztugo, and other single-tablet regimens, along with a PrEP portfolio |
| Oncology | Key growth pillar | Expansion through the Trodelvy antibody-drug conjugate and cell therapies, including the Arcellx acquisition |
| Hepatitis treatments | Legacy business | Antiviral treatments for hepatitis C and hepatitis B |
| Other and inflammation | Complementary business | Diversified areas including COVID-19 treatments and inflammation medicines |
Against a global-scale annual revenue base, HIV treatments remain the company's primary growth pillar. Expanding prescriptions for Biktarvy-centered single-tablet regimens and the launch of new PrEP products such as Yeztugo are driving the growth trend. The oncology pipeline is becoming a medium- to long-term growth pillar through broader Trodelvy indications and the acquisition of cell-therapy assets, while operating margins remain stable. However, amortization of intangible assets related to oncology acquisitions creates pressure on near-term margins.
📐 Gilead Sciences' market cap and company size
Its market capitalization is approximately $163.0B, and it has 17,000명 employees.
As a major U.S. pharmaceutical company ranked among the world's largest by market capitalization, it is often compared with diversified pharmaceutical companies such as PFE, MRK, ABBV, BMY, and JNJ. Gilead Sciences maintains a global-scale market capitalization and continues to return capital through share repurchases and dividends, supported by stable free cash flow.
📈 Gilead Sciences' outlook and stock performance
Prescription growth in the HIV treatment market and progress in the oncology pipeline are the key short- and medium-term variables. Expanded revenue contributions from new PrEP products such as Yeztugo, broader Trodelvy indications in breast cancer and urothelial cancer, and the integration of cell-therapy assets such as Arcellx are medium- to long-term growth drivers. A diversified antiviral and immuno-oncology portfolio also supports the stability of the company's revenue stream. However, the long-term patent-expiration cycle for key products such as Biktarvy, variability in oncology trial results, and the burden of intangible-asset amortization related to acquisitions could create margin volatility in the short and medium term.
- Expanded prescriptions for Yeztugo and other new PrEP products
- Broader Trodelvy indications
- Integration of cell-therapy and immuno-oncology pipelines
⚔️ Gilead Sciences' key competitive strengths and risks
Its leading position in HIV treatments and its diversified antiviral and oncology pipeline are major strengths, while patent expirations and clinical volatility are the key risks.
💪 Key strengths
⚠️ Key risks
🔄 Gilead Sciences' competitors and related stocks
Direct competitors include MRK in HIV treatments, BMY in immuno-oncology and oncology, PFE with its broad antibody-drug conjugate and oncology portfolio, ABBV in antibody-drug conjugates and immunology, and JNJ in diversified pharmaceuticals and consumer health. Other related stocks include oncology and biotechnology companies REGN and VRTX, as well as pharmaceutical distributor MCK, which are often compared alongside Gilead based on prescription cycles and drug-pricing policy trends.
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| MRK | Merck & Co Inc | $129.79 | -0.4% | $320.6B | 36.5 | 7.0 | 18.97% | 2.52% |
| BMY | Bristol-Myers Squibb Co | $64.86 | +2.8% | $132.4B | 18.2 | 6.6 | 38.84% | 3.89% |
| PFE | Pfizer Inc | $24.91 | -0.9% | $142.0B | 19.1 | 1.6 | 8.29% | 6.91% |
| ABBV | Abbvie Inc | $257.41 | -2.2% | $454.8B | 127.0 | - | 15221.82% | 2.67% |
| JNJ | Johnson & Johnson | $255.82 | -3.7% | $616.5B | 29.6 | 7.3 | 25.74% | 2.1% |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc | $738.34 | +6.2% | $77.4B | 18.0 | 2.5 | 14.55% | 0.53% |
| VRTX | Vertex Pharmaceuticals Inc | $481.69 | -0.3% | $122.3B | 28.6 | 6.3 | 24.2% | - |
| MCK | Mckesson Corp | $865.51 | -2.6% | $101.3B | 22.5 | - | - | 0.36% |
✅ Key points for Gilead Sciences investors
These are the main points to monitor when investing in Gilead Sciences. Prescription growth in the HIV market, oncology trial progress, and the patent-expiration cycle are the key short- and medium-term variables. Investors should also monitor the burden of acquisition-related intangible-asset amortization and the consistency of the company's capital-return policy.
| Key point | What to check | Current status |
|---|---|---|
| 💊 HIV revenue | Prescription growth for Biktarvy and Yeztugo | Growth trend maintained |
| 🔬 Oncology pipeline | Trodelvy indications and cell-therapy trial progress | Expansion phase |
| 💰 Capital returns | Share-repurchase and dividend trends | Consistent capital returns |
| 📉 Margin trends | Intangible-asset amortization and R&D expense trends | Requires monitoring |
Long-term patent expirations for key HIV products may contribute to revenue volatility, while oncology and cell-therapy trial results could affect the value of the pipeline. Acquisition-related intangible-asset amortization and changes in U.S. drug-pricing and insurance-reimbursement policies may also affect near-term margins and prescription profitability.
Gilead Sciences is a large-cap pharmaceutical core holding that combines a leading HIV treatment franchise with expanding oncology and cell-therapy pipelines. Clinical results, patent cycles, and drug-pricing policy are the key variables to monitor, and staged buying with a long-term perspective is recommended.
이 글은 2026년 5월 21일 기준 정보입니다.